INGA
Lead Participant:
ATDBIO LIMITED
Abstract
Flexmers are next generation aptamers and provide a novel alternative to drug compounds. To enable a very quick and efficient process for flexmer development, ATDBio and Biaffin will combine their expertise to create an integrated drug discovery pipeline for flexmers.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| ATDBIO LIMITED | £498,050 | £ 249,025 |
People |
ORCID iD |
| Joanna Sobek Brown (Project Manager) |